4 research outputs found
Deciphering biomarkers for leptomeningeal metastasis in malignant hemopathies (Lymphoma/Leukemia) patients by comprehensive multipronged proteomics characterization of cerebrospinal fluid
In the present work, leptomeningeal disease, a very destructive form of systemic cancer, was characterized from several proteomics points of view. This pathology involves the invasion of the leptomeninges by malignant tumor cells. The tumor spreads to the central nervous system through the cerebrospinal fluid (CSF) and has a very grim prognosis; the average life expectancy of patients who suffer it does not exceed 3 months. The early diagnosis of leptomeningeal disease is a challenge because, in most of the cases, it is an asymptomatic pathology. When the symptoms are clear, the disease is already in the very advanced stages and life expectancy is low. Consequently, there is a pressing need to determine useful CSF proteins to help in the diagnosis and/or prognosis of this disease. For this purpose, a systematic and exhaustive proteomics characterization of CSF by multipronged proteomics approaches was performed to determine different protein profiles as potential biomarkers. Proteins such as PTPRC, SERPINC1, sCD44, sCD14, ANPEP, SPP1, FCGR1A, C9, sCD19, and sCD34, among others, and their functional analysis, reveals that most of them are linked to the pathology and are not detected on normal CSF. Finally, a panel of biomarkers was verified by a prediction model for leptomeningeal disease, showing new insights into the research for potential biomarkers that are easy to translate into the clinic for the diagnosis of this devastating disease.We gratefully acknowledge financial support from the Spanish Health Institute, Carlos III (ISCIII), for the grants: FIS PI14/01538, FIS PI17/01930 and CB16/12/00400. We also acknowledge Fondos FEDER (EU) and Junta Castilla-LeĂłn (COVID-19 grant COV20EDU/00187). The Proteomics Unit belongs to ProteoRed, PRB3-ISCIII, supported by grant PT17/0019/0023 of the PE I + D + I2017-2020, funded by ISCIII and FEDERâNorma Galicia is supported by the CONACYT Program. P. Juanes-Velasco is supported by JCYL PhD Program âNos Impulsa-JCYLâ and scholarship JCYLEDU/601/2020
A simple immunoassay for extracellular vesicle liquid biopsy in microliters of nonâprocessed plasma
Background: Extracellular vesicles (EVs), released by most cell types, provide an excellent source of biomarkers in
biological fluids. However, in order to perform validation studies and screenings of patient samples, it is still necessary
to develop general techniques permitting rapid handling of small amounts of biological samples from large numbers
of donors.
Results: Here we describe a method that, using just a few microliters of patientâs plasma, identifies tumour markers
exposed on EVs. Studying physico-chemical properties of EVs in solution, we demonstrate that they behave as stable
colloidal suspensions and therefore, in immunocapture assays, many of them are unable to interact with a stationary
functionalised surface. Using flocculation methods, like those used to destabilize colloids, we demonstrate that
cationic polymers increase EV ζ-potential, diameter, and sedimentation coefficient and thus, allow a more efficient
capture on antibody-coated surfaces by both ELISA and bead-assisted flow cytometry. These findings led to optimization
of a protocol in microtiter plates allowing effective immunocapture of EVs, directly in plasma without previous
ultracentrifugation or other EV enrichment. The method, easily adaptable to any laboratory, has been validated using
plasma from lung cancer patients in which the epithelial cell marker EpCAM has been detected on EVs.
Conclusions: This optimized high throughput, easy to automate, technology allows screening of large numbers of
patients to phenotype tumour markers in circulating EVs, breaking barriers for the validation of proposed EV biomarkers
and the discovery of new ones
MAPK inhibitors dynamically affect melanoma release of immune NKG2D-ligands, as soluble protein and extracellular vesicle-associated
Metastatic melanoma presents, in many cases, oncogenic mutations in BRAF, a MAPK involved in proliferation of tumour cells. BRAF inhibitors, used as therapy in patients with these mutations, often lead to tumour resistance and, thus, the use of MEK inhibitors was introduced in clinics. BRAFi/MEKi, a combination that has modestly increased overall survival in patients, has been proven to differentially affect immune ligands, such as NKG2D-ligands, in drug-sensitive vs. drug-resistant cells. However, the fact that NKG2D-ligands can be released as soluble molecules or in extracellular vesicles represents an additional level of complexity that has not been explored. Here we demonstrate that inhibition of MAPK using MEKi, and the combination of BRAFi with MEKi in vitro, modulates NKG2D-ligands in BRAF-mutant and WT melanoma cells, together with other NK activating ligands. These observations reinforce a role of the immune system in the generation of resistance to directed therapies and support the potential benefit of MAPK inhibition in combination with immunotherapies. Both soluble and EV-associated NKG2D-ligands, generally decreased in BRAF-mutant melanoma cell supernatants after MAPKi in vitro, replicating cell surface expression. Because potential NKG2D-ligand fluctuation during MAPKi treatment could have different consequences for the immune response, a pilot study to measure NKG2D-ligand variation in plasma or serum from metastatic melanoma patients, at different time points during MAPKi treatment, was performed. Not all NKG2D-ligands were equally detected. Further, EV detection did not parallel soluble protein. Altogether, our data confirm the heterogeneity between melanoma lesions, and suggest testing several NKG2D-ligands and other melanoma antigens in serum, both as soluble or vesicle-released proteins, to help classifying immune competence of patients